speedy/RINGO cell cycle regulator family member E5Genealiases: []
Q-omics provides the consensus-scored SPDYE5 profile across patient tissues and cancer cell-line models. SPDYE5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPDYE5 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, SPDYE5 RNA expression shows 19,835 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where SPDYE5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPDYE5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPDYE5 survival associations across molecular data types. SPDYE5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPDYE5 RNA expression–survival associations across cancer types. High SPDYE5 expression shows unfavorable associations in KIRC, KICH, CESC, LGG and LIHC, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPDYE5 RNA expression.
This table summarizes SPDYE5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SPDYE5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPDYE5 shows higher tumor expression in HNSC, KIRC, BLCA, COAD, LIHC and CHOL. The HNSC box plot shows higher SPDYE5 RNA expression in tumor versus normal tissue (log2 FC = +0.107, t-test p < 0.001).
This table shows molecular features associated with SPDYE5 in patient tissues and cancer cell lines. In patient samples, SPDYE5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPDYE5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma.
